SCHEMBL19357751

SCHEMBL19357751

N#CN1Cc2cccc(-c3ccc(Cl)cc3C(N)=O)c2C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BTK Q06187 3/20 0.44
HSP90AA1 P07900 1/20 0.41
KDM4E B2RXH2 2/20 0.38
ADRA1D P25100 7/20 0.37
TEAD1 P28347 3/20 0.36
TEAD4 Q15561 3/20 0.36
TEAD2 Q15562 3/20 0.36
TEAD3 Q99594 1/20 0.36
ADRA1A P35348 2/20 0.36
ADRA2B P18089 1/20 0.36
ADRA1B P35368 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
USP7 Q93009 1/20 0.35
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29710091 1.00 BTK (0.44) BTKHSP90AA1KDM4EADRA1DTEAD1
SCHEMBL19357628 0.87 BTK (0.43) BTKADRA1DTEAD1TEAD4TEAD2
SCHEMBL19357663 0.87 BTK (0.46) BTKTEAD1TEAD4TEAD2TEAD3
SCHEMBL19357627 0.87 BTK (0.46) BTKTEAD1TEAD4TEAD2TEAD3
SCHEMBL29710321 0.87 BTK (0.43) BTKADRA1DTEAD1TEAD4TEAD2
SCHEMBL19357939 0.86 BTK (0.44) BTKKDM4ETEAD1TEAD4TEAD2
SCHEMBL29710124 0.84 TEAD1 (0.39) BTKHSP90AA1KDM4ETEAD1TEAD4
SCHEMBL19357643 0.84 TEAD1 (0.39) BTKHSP90AA1KDM4ETEAD1TEAD4
SCHEMBL19357959 0.81 BTK (0.39) BTKTEAD1TEAD4TEAD2TEAD3
SCHEMBL19374771 0.81 BTK (0.45) BTKTEAD1TEAD4TEAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108698992-B 2-cyanoisoindoline derivatives for the treatment of cancer 特殊治疗有限公司 2022-04-19 CN claimed
EP-3429994-B1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LTD (GB) 2021-06-16 EP claimed
US-10683269-B2 2-cyanoisoindoline derivatives for treating cancer MISSION THERAPEUTICS LIMITED (GB) 2020-06-16 US claimed
EP-3429994-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER Mission Therapeutics Limited (GB) 2019-01-23 EP claimed
US-20190010122-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2019-01-10 US claimed
WO-2017158388-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2017-09-21 WO claimed
CN-108698992-B 2-cyanoisoindoline derivatives for the treatment of cancer 特殊治疗有限公司 2022-04-19 CN disclosed
EP-3429994-B1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LTD (GB) 2021-06-16 EP disclosed
US-10683269-B2 2-cyanoisoindoline derivatives for treating cancer MISSION THERAPEUTICS LIMITED (GB) 2020-06-16 US disclosed
EP-3429994-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER Mission Therapeutics Limited (GB) 2019-01-23 EP disclosed
US-20190010122-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2019-01-10 US disclosed
WO-2017158388-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER MISSION THERAPEUTICS LIMITED (GB) 2017-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010122-A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER USP7, USP47, USP2 BTK 3846/4885HSP90AA1 3065/4885KDM4E 352/4885
US-10683269-B2 2-cyanoisoindoline derivatives for treating cancer USP7, USP47, USP2 BTK 3846/4885HSP90AA1 3065/4885KDM4E 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.